港股異動丨興科蓉醫藥(6833.HK)續升超11% 股價刷新歷史新高
格隆匯11月15日丨興科蓉醫藥(6833.HK)再度拉昇漲11.27%, 4日累計升幅超50%。報1.58港元再度刷新歷史高價,總市值近30億港元。公司作為國內血液製品賽道中已佔據領頭地位,此前與北京諾康達合作開始研發少女針,可以算是已經正式跨入醫美賽道。業內人士指出,相信在興科蓉醫藥血液製品業務良好發展的基礎下,其醫美業務有望為公司帶來強勁可持續的業績增長,值得市場所關注。此外,除了在此次新佈局醫美板塊以外,其在原本的血液製品行業中也處於持續發展的階段。從其上市以來的營業收入可以看出,公司一直保持着穩健增長趨勢。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.